New drug combo tested for Tough-to-Treat blood cancers
Disease control
Terminated
This study tested whether adding a drug called selinexor to standard chemotherapy or an immunotherapy drug (tislelizumab) could help control advanced T-cell and NK-cell lymphomas that had returned or stopped responding to prior treatments. It involved adults whose cancer had come…
Phase: PHASE1, PHASE2 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC